Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

GlobeNewswire November 29, 2019

Y-mAbs Announces Update on Omburtamab in DSRCT

GlobeNewswire November 15, 2019

Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

GlobeNewswire November 13, 2019

Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

GlobeNewswire November 6, 2019

Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 1, 2019

Y-mAbs Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 29, 2019

Y-mAbs Announces Proposed Public Offering of Common Stock

GlobeNewswire October 29, 2019

Y-mAbs Announces Positive Omburtamab Clinical Data

GlobeNewswire October 28, 2019

Y-mAbs Announces Naxitamab Update

GlobeNewswire October 25, 2019

Y-mAbs Announces Data to be Presented at 2019 CTOS

GlobeNewswire August 30, 2019

Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

GlobeNewswire August 14, 2019

Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14

GlobeNewswire August 7, 2019

Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab

GlobeNewswire July 8, 2019

Y-mAbs Announces Recruitment Status for Pivotal Trials

GlobeNewswire July 1, 2019

Y-mAbs Secures Commercial Radiolabeling Capacity

GlobeNewswire July 1, 2019

Y-mAbs Announces Data to be Presented at 2019 SIOP

GlobeNewswire June 26, 2019

Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting

GlobeNewswire May 15, 2019

Y-mAbs Announces Development Update on Cancer Vaccine Program

GlobeNewswire May 14, 2019

Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments

GlobeNewswire May 10, 2019

Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas

GlobeNewswire May 8, 2019